DE69623755D1 - Pharmazeutika und assays die enzymeuntereinheiten anwenden - Google Patents

Pharmazeutika und assays die enzymeuntereinheiten anwenden

Info

Publication number
DE69623755D1
DE69623755D1 DE69623755T DE69623755T DE69623755D1 DE 69623755 D1 DE69623755 D1 DE 69623755D1 DE 69623755 T DE69623755 T DE 69623755T DE 69623755 T DE69623755 T DE 69623755T DE 69623755 D1 DE69623755 D1 DE 69623755D1
Authority
DE
Germany
Prior art keywords
agent
assays
sub units
constituted
components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69623755T
Other languages
English (en)
Other versions
DE69623755T2 (de
Inventor
Richard William Titball
Francis Joseph-Eclagen Li Carr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovation Ltd
Original Assignee
Biovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovation Ltd filed Critical Biovation Ltd
Application granted granted Critical
Publication of DE69623755D1 publication Critical patent/DE69623755D1/de
Publication of DE69623755T2 publication Critical patent/DE69623755T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69623755T 1995-02-22 1996-02-21 Pharmazeutika und assays die enzymeuntereinheiten anwenden Expired - Fee Related DE69623755T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9503486.4A GB9503486D0 (en) 1995-02-22 1995-02-22 Pharmaceuticals and assays using enzyme subunits
PCT/GB1996/000380 WO1996025952A1 (en) 1995-02-22 1996-02-21 Pharmaceuticals and assays using enzyme subunits

Publications (2)

Publication Number Publication Date
DE69623755D1 true DE69623755D1 (de) 2002-10-24
DE69623755T2 DE69623755T2 (de) 2003-06-05

Family

ID=10770034

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69623755T Expired - Fee Related DE69623755T2 (de) 1995-02-22 1996-02-21 Pharmazeutika und assays die enzymeuntereinheiten anwenden

Country Status (15)

Country Link
US (2) US6472365B1 (de)
EP (1) EP0810880B1 (de)
JP (1) JPH11500136A (de)
KR (1) KR19980702499A (de)
CN (1) CN1188704C (de)
AT (1) ATE224204T1 (de)
AU (1) AU714396B2 (de)
CA (1) CA2213566A1 (de)
DE (1) DE69623755T2 (de)
DK (1) DK0810880T3 (de)
ES (1) ES2182962T3 (de)
GB (1) GB9503486D0 (de)
PT (1) PT810880E (de)
WO (1) WO1996025952A1 (de)
ZA (1) ZA961427B (de)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4463090A (en) * 1981-09-30 1984-07-31 Harris Curtis C Cascade amplification enzyme immunoassay
US4900556A (en) 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
GB8528761D0 (en) 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
US4874710A (en) * 1986-02-20 1989-10-17 Becton Dickinson And Company Assay and product in which binder and liposomes are supported on a solid support
EP0301333A3 (de) 1987-07-29 1992-07-01 Abbott Laboratories Auf liposomen basierter, homogener Immunoassay für diagnostische Teste
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
JPH04200632A (ja) 1990-11-29 1992-07-21 Toyo Ink Mfg Co Ltd リポソームの破壊方法
JPH0556797A (ja) 1991-08-31 1993-03-09 Toyo Ink Mfg Co Ltd リポソーム破壊物質の検出方法
US5277913A (en) * 1991-09-09 1994-01-11 Thompson David H Liposomal delivery system with photoactivatable triggered release
CA2163860A1 (en) * 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes

Also Published As

Publication number Publication date
CN1188704C (zh) 2005-02-09
ATE224204T1 (de) 2002-10-15
EP0810880A1 (de) 1997-12-10
AU714396B2 (en) 2000-01-06
JPH11500136A (ja) 1999-01-06
DE69623755T2 (de) 2003-06-05
WO1996025952A1 (en) 1996-08-29
US6472365B1 (en) 2002-10-29
KR19980702499A (ko) 1998-07-15
ZA961427B (en) 1996-08-07
DK0810880T3 (da) 2003-01-06
ES2182962T3 (es) 2003-03-16
US20020035084A1 (en) 2002-03-21
PT810880E (pt) 2003-02-28
AU4725996A (en) 1996-09-11
EP0810880B1 (de) 2002-09-18
US6974699B2 (en) 2005-12-13
GB9503486D0 (en) 1995-04-12
CA2213566A1 (en) 1996-08-29
CN1182372A (zh) 1998-05-20

Similar Documents

Publication Publication Date Title
Ekong et al. Recombinant SINAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro
Vaandrager et al. Guanylyl cyclase C is an N-linked glycoprotein receptor that accounts for multiple heat-stable enterotoxin-binding proteins in the intestine.
Bade et al. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates
DE69838979D1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
ES2171705T3 (es) Complejos de polipeptido-dendrimero.
DE69407402D1 (de) Repamycinbestimmung
ES8606663A1 (es) Un procedimiento de ensayo inmunometrico para detectar la presencia de al menos dos antigenos en una muestra
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
Williamson et al. Neuronal sensitivity to tetanus toxin requires gangliosides
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
ATE314462T1 (de) Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
Keil et al. Biogenesis of the mitochondrial receptor complex. Two receptors are required for binding of MOM38 to the outer membrane surface.
DE60044420D1 (de) Enzym-Protein-Komplex
DE60137347D1 (de) Neuer immunogener komplex
Wine et al. Identification of components of protein complexes using a fluorescent photo-cross-linker and mass spectrometry
Hughes et al. Utilization of a recombinant substrate rAgg1 to study the biochemical properties of aggrecanase in cell culture systems
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
Paul et al. Site specificity of a catalytic vasoactive intestinal peptide antibody. An inhibitory vasoactive intestinal peptide subsequence distant from the scissile peptide bond.
DE69623755D1 (de) Pharmazeutika und assays die enzymeuntereinheiten anwenden
Jensen et al. Biochemical characterization and lysosomal localization of the mannose-6-phosphate protein p76 (hypothetical protein LOC196463)
Viereck et al. Characterization of a cholecystokinin 8-generating endoprotease purified from rat brain synaptosomes.
Shime et al. Association of Pasteurella multocida toxin with vimentin
Barrieux et al. Nonidentity of the 48,000-dalton protein of mRNA-protein particles and the beta subunit of eukaryotic initiation factor 2.
Liu et al. Primary structure of a human IgA1 immunoglobulin. III. Isolation, composition, and amino acid sequence of the thermolysin peptides.
Choumet et al. Production of an immunoenzymatic tracer combining a scFv and the acetylcholinesterase of Bungarus fasciatus by genetic recombination

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee